STOCK TITAN
  1. Home
  2. News
  3. AIM

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.

AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.

In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.

AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.

The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.

For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.

News

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Rhea-AI Summary
AIM ImmunoTech Inc. has received authorization from the Erasmus Medical Center Ethics Committee to open a European site for the ongoing Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer. The approval is a significant step towards enrolling subjects in the European arm of the clinical trial. The study aims to compare the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Subject enrollment is expected in Q1 2024, with approximately 90 subjects to be enrolled in the United States and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
clinical trial
-
News

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Rhea-AI Summary
AIM ImmunoTech Inc. announced the enrollment of the first subject in a Phase 1b/2 clinical trial combining Ampligen with AstraZeneca’s Imfinzi for late-stage pancreatic cancer treatment. Positive clinical data could make AIM an attractive buyout target. AIM secured a U.S. patent for Ampligen's use in combination therapy. The trial aims to determine safety and clinical benefit rates of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the opening of enrollment in a Phase 1b/2 clinical trial at Erasmus Medical Center in Rotterdam, Netherlands, for the treatment of pancreatic cancer. The trial will combine AIM's Ampligen with AstraZeneca's Imfinzi, aiming to determine the safety and clinical benefit rate of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announces the election of all four directors at the 2023 Annual Meeting of Stockholders. The company expresses gratitude to shareholders and emphasizes commitment to delivering life-saving treatments and creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

Rhea-AI Summary
Court Found that Several AIM Advance Notice Bylaws Are Invalid. The Delaware Court of Chancery ruled in favor of the Kellner Group, finding four separate advance notice bylaw provisions adopted by AIM Immunotech Inc. to be invalid. However, the Court also found that Mr. Kellner's notice of nominations did not comply with certain remaining advance notice provisions. AIM announced that it will disregard the Kellner Group's nominations, and any proxies voted in favor of the Kellner Group nominees will not be recognized or tabulated at the Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the Delaware Court of Chancery ruled against the Activist Group's nomination notice, finding it invalid under the Company's Bylaws. The Court upheld the Board's decision to reject the notice due to omissions and misleading information. AIM will reconvene its 2023 Annual Meeting and adjourn until January 5th, disregarding any proxies submitted by the Activist Group. The Board urges shareholders to vote for all four Company Directors on the WHITE Proxy Card.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
News

AIM ImmunoTech Provides Update Regarding Annual Meeting

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) will convene its 2023 Annual Meeting of Stockholders on December 1st, adjourning until December 29th to await a ruling from the Delaware Court of Chancery regarding litigation brought against the Company and its directors by an Activist Group seeking to nominate three candidates for election to AIM's Board of Directors. The Board has determined the Activist Group's nomination notice as invalid and will disregard any proxies or votes cast for the individuals on the Activist Group's proxy card unless the litigation results in a finding that the Notice is valid. The record date for determining shareholders eligible to vote at the 2023 Annual Meeting remains October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
-
News

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) extends exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 with the issuance of U.S. patents No. 11,813,279 and 11,813,281. The patents cover novel methods for cancer therapy and improving exercise tolerance in ME/CFS patients. AIM's CEO, Thomas K. Equels, emphasizes the potential financial future of the company and the driving force behind multiple clinical studies in oncology, ME/CFS, and Post-COVID conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announced the completion of dosing in the Phase 2 study for Ampligen® as a potential therapeutic for Post-COVID fatigue. No severe adverse events reported. Topline data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
clinical trial covid-19
News

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change

Rhea-AI Summary
AIM Immunotech Inc. (NYSE American: AIM) - The Kellner Group urges stockholders to act against the entrenched Board's reckless spending and self-interested behavior. The Board has wasted $15 million in the past two years to prevent stockholders from voting on Board nominations and has failed to engage in dialogue to avoid this destructive and wasteful path. The Kellner Group, owning 6.5% of outstanding shares, is fully aligned with stockholders and brings the skills, experience, and credibility necessary for AIM to succeed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.1383 as of February 21, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 9.8M.

What is AIM ImmunoTech's main focus?

AIM ImmunoTech focuses on developing therapeutics to treat various cancers, immune disorders, and viral diseases, including COVID-19.

What are AIM ImmunoTech's key products?

The company's key products include Ampligen (rintatolimod), a TLR3 agonist immuno-modulator for cancer and viral diseases, and Alferon N Injection for treating genital warts.

What recent achievements has AIM ImmunoTech made?

Recent achievements include positive interim data for Ampligen combined with Keytruda in ovarian cancer treatment, and the successful manufacturing of over 9,000 clinical vials of Ampligen.

Who are AIM ImmunoTech's notable partners?

AIM ImmunoTech has research agreements with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. for developing Ampligen as a COVID-19 therapy.

What clinical trials is AIM ImmunoTech currently conducting?

The company is conducting clinical trials for various cancers, chronic fatigue syndrome, and COVID-19 related conditions.

How can investors access AIM ImmunoTech's financial reports?

Investors can access financial reports on AIM ImmunoTech's official website and the U.S. Securities and Exchange Commission (SEC) filings.

How does AIM ImmunoTech engage with its stakeholders?

AIM ImmunoTech engages stakeholders through regular updates, CEO Corner segments, and social media platforms like X, LinkedIn, and Facebook.

What is the significance of Ampligen in AIM ImmunoTech's portfolio?

Ampligen is a cornerstone of AIM ImmunoTech's portfolio, showing broad-spectrum activity in clinical trials for cancers, viral diseases, and immune disorders.

Who leads AIM ImmunoTech?

The company is led by CEO Thomas K. Equels, who focuses on advancing the company's pipeline and achieving clinical and commercial success.

Where can more information about AIM ImmunoTech be found?

More information can be found on the company's official website, aimimmuno.com, and its social media channels.
Stock AIM logo
Aim Immunotech

NYSE:AIM

AIM Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AIM Stock Data

9.82M
62.54M
8.57%
14.08%
0.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA